A Predictive Risk Score for Predicting Capecitabine-Induced Hand-Foot Syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20250410001

Enrollment

490

Registered

2025-04-10

Start date

2025-04-17

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer patients who were treated with capecitabine Cancer patients , capecitabine, hand-foot syndrome, prognostic prediction model

Interventions

Cancer patients who were treated with capecitabine at the Division of Medical Oncology, Buddhasothorn Hospital

Prevention

Cancer patients

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Cancer patients who were planned to received at the first cycle of capecitabine-based chemotherapy regimen 2.Age > 18 years old

Exclusion criteria

Exclusion criteria: 1.Patients who received <2 cycles of capecitabine-based chemotherapy and were subsequently lost to follow-up

Design outcomes

Primary

Measure	Time frame
Hand-foot syndrome grade 2-3 after receiving capecitabine treatment CT-CAE version 5.0 grading for Hand foot syndrome	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactChaichana Chantharakhit

Buddhasothorn hospital

chaichana.md@gmail.com0817866945

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026